Form 4: Arcturus Therapeutics Director Edward W. Holmes Reports Stock Transactions

Director Edward W. Holmes reports acquisition of stock options and deferred stock units conversion to common stock in Arcturus Therapeutics Holdings Inc.

Summary

• On June 14, 2024, Edward W. Holmes, a director of Arcturus Therapeutics Holdings Inc., reported transactions involving the company's stock.
• Holmes acquired 3,131 shares of common stock upon the vesting and conversion of deferred stock units.
• These deferred stock units were part of the 2023 annual grant and vested at the company's 2024 annual meeting of stockholders.
• Additionally, Holmes acquired options to purchase 15,000 shares of common stock, which vest monthly over one year from the grant date of June 14, 2024.
• The exercise price of these options is $31 per share.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing detailing stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to investors regarding the ownership positions and transactions of key individuals within the company.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions, which can influence investor confidence.

Key Dates